

AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA259)

NICE GUIDANCE ISSUED JUNE 2012

(Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology)

Final Appraisal Recommendation

Advice No: 0612 – February 2012

Abiraterone (Zytiga[®]▼)

Submission by: Janssen Cilag Ltd

Recommendation of AWMSG

Abiraterone (Zytiga[®]▼) with prednisone or prednisolone is recommended for the treatment of metastatic castration resistant prostate cancer in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.

This recommendation applies only in circumstances where the approved Wales Patient Scheme for access to medicines is utilised.

AWMSG is of the opinion that abiraterone (Zytiga[®]▼) is suitable for specialist only prescribing within NHS Wales for the above indication.

In reaching this recommendation AWMSG took account of the AWMSG Secretariat Assessment Report, the preliminary appraisal recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion, lay/patient/carer perspective and discussions at AWMSG.

This recommendation was ratified by the Minister for Health and Social Services on 17th February 2012 and will be considered for review in February 2015.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group Final Appraisal Recommendation – 0612: Abiraterone (Zytiga[®]▼) February 2012